Connexins as therapeutic targets in neurological and neuropsychiatric disorders.
Astrocyte
CNS drugs
Connexin-modulating drugs
Connexins
Gap junctions
Hemichannels
Neurodegenerative diseases
Neuropsychiatric diseases
Journal
Biochimica et biophysica acta. Molecular basis of disease
ISSN: 1879-260X
Titre abrégé: Biochim Biophys Acta Mol Basis Dis
Pays: Netherlands
ID NLM: 101731730
Informations de publication
Date de publication:
01 05 2021
01 05 2021
Historique:
received:
05
10
2020
revised:
06
01
2021
accepted:
19
01
2021
pubmed:
6
2
2021
medline:
11
9
2021
entrez:
5
2
2021
Statut:
ppublish
Résumé
Astrocytes represent the reticular part of the central nervous system; gap junctions formed by connexins Cx43, Cx30- and Cx26 provide for homocellular astrocyte-astrocyte coupling, whereas connexins Cx30, Cx32, Cx43, and Cx47 connect astrocytes and oligodendrocytes. Astroglial networks are anatomically and functionally segregated being homologous to neuronal ensembles. Connexons, gap junctions and hemichannels (unpaired connexons) are affected in various neuropathologies from neuropsychiatric to neurodegenerative diseases. Manipulation of astrocytic connexins modulates the size and outreach of astroglial syncytia thus affecting astroglial homeostatic support. Modulation of astrocytic connexin significantly modifies pharmacological profile of many CNS drugs, which represents an innovative therapeutic approach for CNS disorders; this approach is now actively tested in pre-clinical and clinical studies. Wide combination of connexin modulators with CNS drugs open new promising perspectives for fundamental studies and therapeutic strategies.
Identifiants
pubmed: 33545299
pii: S0925-4439(21)00031-4
doi: 10.1016/j.bbadis.2021.166098
pii:
doi:
Substances chimiques
Connexins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
166098Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.